Results 11 to 20 of about 91,870 (284)

Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration [PDF]

, 2020
Background Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related to the
Maestro, Alessandra, Marcuzzi, Annalisa, Maximova, Natalia, Zanon, Davide   +3 more
core   +1 more source

Safety aspects of infliximab in inflammatory bowel disease patients - A retrospective cohort study in 100 patients of a German University Hospital [PDF]

, 2004
Background: Infliximab, a chimeric anti-tumour necrosis factor monoclonal antibody with potent anti-inflammatory effects, represents an effective treatment option in patients with severe inflammatory bowel disease (IBD).
Ali Y, Baker D, Burkhard Göke, Cohen RD, Hanauer S, Hommes DW, Jani AL, Julia Seiderer, Puchner TC, Sample C, Sandborn WJ, Thomas Ochsenkühn   +11 more
core   +1 more source

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

BMC Musculoskeletal Disorders, 2011
Background This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusioncycle to assess at what moment patients develop low/no infliximab trough levels and ...
van Riel Piet LCM, Hekster Yechiel A, Wolbink GJ, den Broeder Alfons A, van den Bemt Bart JF, Benraad Bart, van den Hoogen Frank HJ   +6 more
doaj   +1 more source

Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.

مجلة كلية الطب, 2015
Background: Rheumatoid arthritis is a common chronic and destructive autoimmune arthropathy .Treatment with infliximab gives great improvement to a large numbers of patients with RA ,however, in some patients after prolonged treatment infliximab can ...
Mohammed A. Al-Karkhi, Muhammed M. Al-Ani, Nizar A. Jassim   +2 more
doaj   +1 more source

Forced Degradation Testing as Complementary Tool for Biosimilarity Assessment [PDF]

, 2019
Oxidation of monoclonal antibodies (mAbs) can impact their efficacy and may therefore represent critical quality attributes (CQA) that require evaluation.
Dyck, Yan Felix Karl, Jabs, Wolfgang, Joseph, Jan Felix, Parr, Maria Kristina, Rehm, Daniel, Sandig, Volker, Winkler, Karsten   +6 more
core   +1 more source

Infliximab

Reactions Weekly, 2006
europepmc   +5 more sources

Infliximab-induced retrobulbar optic neuritis in a patient with ankylosing spondylitis

GMS Ophthalmology Cases, 2023
Objective: To present a case with infliximab-induced retrobulbar optic neuritis.Case description: A 58-year-old woman presented to our clinic with a two-day history of blurred vision in her right eye.
Dündar, Sema, Yaşar, Mimbay, Çakmak, Harun, Kıylıoğlu, Nefati, Ünsal, Alparslan   +4 more
doaj   +1 more source

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study

BMC Musculoskeletal Disorders, 2012
Background To get insight in the prevalence of high, or low/no serum infliximab trough levels in patients with low disease activity and if serum trough levels are stable and reliable longitudinally we conducted a prospective cohort study Methods In a ...
van der Maas Aatke, van den Bemt Bart JF, Wolbink Gertjan, van den Hoogen Frank HJ, van Riel Piet LCM, den Broeder Alfons A   +5 more
doaj   +1 more source

Viewpoint on handling anti-TNF failure in psoriasis [PDF]

, 2013
An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases,
BRACKE, STEFANIE, Lambert, Jo
core   +1 more source

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.

PLoS ONE, 2015
ObjectiveIn patients with postoperative recurrence of Crohn's disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg).
Dario Sorrentino, Marco Marino, Themistocles Dassopoulos, Dimitra Zarifi, Tiziana Del Bianco   +4 more
doaj   +1 more source